A Study of ZN-c3 in Participants With Solid Tumors

Eligibility Criteria

• 1. Subjects must have a solid tumor with advanced or metastatic disease, refractory to standard therapy or for whom no standard therapy is available, or the subject is ineligible for standard therapy(ies).
• 2. Measurable or evaluable disease per RECIST version 1.1.
• 1. Prior therapy with ZN-c3 or known hypersensitivity to any drugs similar to ZN-c3 in class or any inactive ingredients present in ZN-c3.
• 2. Prior therapy with a WEE1 inhibitor.
• 3. A serious illness or medical condition(s).
• 4. Unresolved toxicity of Grade \>1 attributed to any prior therapies (excluding Grade ≤2 neuropathy, alopecia or skin pigmentation).
• 5. Pregnant or lactating females (including the cessation of lactation) or females of childbearing potential who have a positive serum pregnancy test within 14 days prior to C1D1.
• 6. Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
• 7. 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of \>480 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.
• 8. History or current evidence of congenital or family history of long QT syndrome or Torsade de Pointes (TdP).